Diamyd Medical’s former sister company secures new financing
Diamyd Medical holds shares in the US gene therapy company Periphagen Holdings, Inc. Periphagen has announced the successful completion of a financing transaction where a life science fund invests up to USD 16 million, of which USD 6.5 million has been closed.“The money and expertise that the fund brings significantly increase the chances of successful development of Periphagen’s gene therapy platform,” says Peter Zerhouni, President and CEO of Diamyd Medical. “Diamyd Medical will benefit from that in several ways as, apart from being a shareholder, we have other financial interests in the